MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. 2017

Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
Department of Urology, The 1st Affiliated Hospital of Zhengzhou UniversityNO. 1 East Build Road, Zhengzhou 450052, Henan, China.

Current evidence indicates that microRNAs are widely down-regulated in various tumors including colorectal carcinoma, liver cancer and lung cancer, and function as tumor suppressors through inhibiting cancer cell growth, invasion and migration. Here, we demonstrated that miR-210-3p level was significantly reduced in the bladder cancer compared to paratumor tissues, and attempt to reveal the regulatory role of miR-210-3p in bladder cancer progression. Exogenous overexpression of miR-210-3p inhibited the proliferation, migration and invasion of bladder cancer cells in vitro. In addition, the nude mouse xenograft model showed that miR-210-3p over-expressing inhibited bladder cancer growth and liver metastasis whereas silencing miR-210-3p caused an opposite outcome, which is mainly regulated by targeting fibroblast growth factor receptor-like 1 (FGFRL1). We also demonstrated that the expression of FGFRL1 in bladder cancer specimens were negatively correlated with miR-210-3p level, and FGFRL1 overexpression rescued the cell proliferation and invasion inhibited by ectopic expression of miR-210-3p. Moreover, knockdown of FGFRL1 was able to mimic the cell growth and metastasis effects induced by miR-210-3p over-expressing in bladder cancer cells. Together, these results indicate that miR-210-3p plays an important role in the regulation of bladder cancer growth and metastasis in vitro and in vivo through targeting FGFRL1.

UI MeSH Term Description Entries

Related Publications

Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
January 2014, PloS one,
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
January 2011, The Journal of biological chemistry,
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
November 2016, Oncology reports,
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
September 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
February 2019, Anatomical record (Hoboken, N.J. : 2007),
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
July 2020, Anatomical record (Hoboken, N.J. : 2007),
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
January 2013, PloS one,
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
January 2016, OncoTargets and therapy,
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
January 2019, Cancer science,
Xiaoming Yang, and Lei Shi, and Chengzhi Yi, and Yang Yang, and Liansheng Chang, and Dongkui Song
July 2019, Molecular medicine reports,
Copied contents to your clipboard!